Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Deep Brain Stimulation Devices - Global Market Size, Share & Trends Analysis & Forecast to 2025 - ResearchAndMarkets.com

Research and Markets
Posted on: 07 Nov 18

The "Deep Brain Stimulation Devices Market Size, Share & Trends Analysis Report By Application (Pain Management, Epilepsy, Essential Tremor, OCD, Depression, Dystonia, Parkinson's), By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global deep brain stimulation devices market size is expected to reach USD 2.1 billion by 2025, progressing at a CAGR of over 11.9% during the forecast period.

Growing prevalence of Parkinson's disease coupled with surging demand for cost-efficient surgical procedures, minimally invasive in nature, is providing a fillip to the market.

A significant rise in the usage of deep brain stimulators by neurologists in the treatment of various neurological diseases is supplementing the growth of the market. These diseases include Parkinson's disease, obsessive-compulsive disorder, essential tremors, and dystonia.

Pending product approvals from regulatory authorities such as the U.S. FDA for the adoption of DBS in the treatment regime of refractory epilepsy is also estimated to offer significant growth opportunities to the market in the coming years.

Moreover, advent of technologically advanced concepts in DBS systems such as fractionation of electric current and selective current steering, which induces positive patient outcomes, is further projected to fuel market growth prospects.

Key Findings

  • Parkinson's disease accounted for the leading share in the market in 2016 owing to benefits offered by DBS such as improvised motor symptoms for longer time period, fewer side effects, and ability to track momentary fluctuations.
  • Increasing number of drug-resistant cases in treatment of Parkinson's disease is also a major factor escalating the growth of the market.
  • Obsessive-compulsive disorder held the second largest share in terms of revenue as a result of failure of serotonin reuptake inhibitors (SSRi) and positive patient outcomes associated with DBS.

Companies Featured

  • Medtronic PLC
  • Boston Scientific
  • St. Jude Medical Inc.
  • Aleva Neurotherapeutics S.A.

Topics Covered

Chapter 1. Executive Summary

Chapter 2. Deep Brain Stimulators Industry Outlook

Chapter 3. Deep Brain Stimulators Application Outlook

Chapter 4. Deep Brain Stimulators Regional Outlook

Chapter 5. Competitive Landscape

Chapter 6. Methodology and Scope

For more information about this report visit https://www.researchandmarkets.com/research/lr6qfn/deep_brain?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005610/en/

Business Wire
www.businesswire.com

Last updated on: 07/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.